MRI is the modality of choice for depiction and delineation of intracerebral neoplasms. However, tumor specification is limited and sometimes conventional MRI cannot discriminate glioblastomas from solitary metastases, CNS lymphomas, or other glioma grades. Because their management and prognosis are different, early differentiation is important. For this, functional MRI techniques are beneficial.

First-pass dynamic susceptibility-weighted, contrast-enhanced (DSC) magnetic resonance (MR) echo-planar imaging (EPI) is well established for determining relative regional cerebral blood volume (rrCBV) in brain tumors \[[@b1]\]. Perfusion can also be measured by arterial spin-labeling techniques (ASL) that measure relative regional cerebral blood flow (rrCBF) without using extrinsic contrast agents \[[@b2]--[@b4]\]. Dynamic contrast-enhanced (DCE) MRI measures a composite of tumor perfusion, vessel permeability, and extravascular-extracellular space volume. It bases on the acquisition of serial T1-weighted MR images before, during, and after administration of an IV contrast agent \[[@b5]\]. Proton MR spectroscopic imaging (^1^H MRSI) displays the distribution of metabolites within tumor tissue as a molecular image. It shows benefits for the differentiation of neoplastic and non-neoplastic lesions and for glioma grading \[[@b6]--[@b8]\].

Although each functional MRI technique is beneficial for tumor grading, differentiation, and treatment monitoring \[[@b1], [@b5], [@b6]\], a comprehensive analysis of all these techniques with respect to intermodality correlation and predictive power in discriminating glioblastomas from other entities is lacking.

Thus, we present a comprehensive investigation of the functional MRI methods DSC and ASL perfusion MRI, DCE MRI, and MRSI. We assess correlations between histology and functional MRI and evaluate their value to differentiate between a glioblastoma, solitary metastasis, or CNS lymphoma and to correctly grade gliomas.

Methods
=======

Patient enrollment
------------------

Seventy-nine consecutive patients (36 women, 43 men; mean age 57±14 years \[SD\]) with suspected intra-axial brain tumor were included prospectively in the study over 2 years. Suspicion was raised based on unenhanced CT scans that were routinely performed when the patients presented with a new neurologic deficit at the casualty ward of our university's neurology department. Exclusion criteria were any antiedematous or immunosuppressive treatment, surgery, radiation therapy, or chemotherapy of a brain tumor before inclusion in the study. For all patients, it was the first diagnosis of a brain lesion. The patients were then referred for MRI.

The study was approved by the institutional review board and conducted according to the Declaration of Helsinki. Informed consent was obtained from all patients after the nature of the examination had been fully explained.

MRI protocol and data post-processing
-------------------------------------

Two MRI examinations were performed within 1 week prior to surgery prospectively in two imaging centers with 1.5-T MR units using standard circular-polarized head coils within a minimum time interval of 1 day and a maximum interval of 3 days. Two MRI examinations were necessary because of the long imaging time needed for the functional MRI methods under test and the fact that both DCE and DSC MRI require specific contrast medium administration. In all patients, there were no substantial changes in tumor morphology (e.g. caused by intratumoral bleeding) between both MR examinations that would have meant exclusion of the study. With the first MR unit (Edge whole body system, Marconi Medical Systems, Cleveland, OH), standard anatomic MRI and DSC MRI were performed. With the second MR unit (Magnetom Vision Plus, Siemens, Erlangen, Germany), MRSI, ASL, and DCE MRI were performed. The main features of the functional MRI techniques used in our study are given in [Table 1](#T1){ref-type="table"}. Table 1Functional MRI techniques used for brain tumor imagingMRI techniqueAbbreviationParameters measuredMeasurement timeDynamic susceptibility-weightedcontrast-enhanced MRIDSC MRIRelative regional cerebral blood volume52 sArterial spin-labeling MRI (Q2TIPS sequence)ASL MRI (Q2TIPS)Relative regional cerebral blood flow4 min, 42 sArterial spin-labeling MRI (ITS-FAIR sequence)ASL MRI (ITS-FAIR)Relative regional cerebral blood flow,5 min, 3 sarterial transit timeMagnetic resonance spectroscopic imagingMRSICholine, creatine, *N*-acetyl aspartate,11 min, 17 slactate, lipidsDynamic contrast-enhanced MRIDCE MRIAmplitude, exchange rate constant *k*~*ep*~11 min, 56 sQ2TIPS sequence = second version of quantitative imaging of perfusion by using a single subtraction with addition of thin-section periodic saturation after inversion and a time delay sequence; ITS-FAIR sequence = inflow turbo-sampling, echo-planar, flow-sensitive, alternating inversion recovery sequence.

### DSC MRI

Standard MRI and DSC MRI were performed during the same session. Standard T2- (repetition time \[TR\]/echo time \[TE\], 2600 ms /100 ms) and T1-weighted (550 ms /25 ms) images were obtained before DSC MRI, and then contrast-enhanced T1-weighted images were acquired. DSC MRI was performed using a gradient-echo EPI sequence (1300 ms /26 ms). With this sequence, 40 data sets were acquired with a time resolution of 1.3 s per data set. The sequence and the contrast agent injection were started simultaneously. As contrast agent, we used 0.1 mmol /kg body weight of gadolinium-diethylene-triamine-pentaacetic acid (Gd-DTPA) (Magnevist, Schering, Berlin, Germany), which was injected by a pneumatically driven injection pump at an injection rate of 5 mL /s. DSC MRI was analyzed on a workstation (Vistar, Marconi Medical Systems, Cleveland, OH). From the DSC MRI data, we calculated rrCBV values by using contralateral white matter as internal reference \[[@b9]\].

### Spectroscopic imaging

An axial and coronal fluid-attenuated inversion recovery (FLAIR) sequence (9000 ms /105 ms) was used to position the ^1^H two-dimensional MRSI sequence (point-resolved spectroscopy, 1500 ms /135 ms, voxel size 9×9×15mm^3^). Relative signal intensity ratios of choline-containing compounds (Cho), the creatine-phosphocreatine complex (Cr), and *N*-acetyl aspartate (NAA) and metabolic images were calculated using the software SiTools (VA Medical Center, San Francisco, CA). MRSI was performed before contrast-enhanced MRI \[[@b10]\].

### ASL MRI

After MRSI, two pulsed ASL sequences were performed. We used the Q2TIPS sequence (second version of quantitative imaging of perfusion by using a single subtraction with addition of thin-section periodic saturation after inversion and a time delay sequence) \[[@b11]\] that is capable of multislice imaging, such as DSC MRI, but gives no dynamic information about blood inflow. Hence, another ASL sequence was performed after the Q2TIPS sequence. The inflow turbo-sampling, echo-planar FAIR sequence (ITS-FAIR) \[[@b12]\] allows for sampling the inflow of labeled blood into the read-out slice with a temporal resolution of 100 ms and thus yields dynamic information about inflow characteristics and enables quantification of the arterial transit time (ATT). The ITS-FAIR sequence parameters were as follows: TE = 17.7 ms, measurement interval (TR) = 2700 ms, 128×128 matrix, slice thickness 10 mm, 220-mm field of view (FOV), acquisition time of 5 min 3 s for 55 interleaved averages of selective and global inversion series. A time series of 27 CBF-weighted images was acquired with a time delay of 100 ms between two successive images. The first image was acquired at an inflow time of 150 ms. Sequence parameters of Q2TIPS were as follows: TE = 30.5 ms; measurement interval (TR) = 2500 ms; TI = 1200 ms (inversion time); TI2 = 200 ms (time delay between saturation pulse and image acquisition); slice thickness, 8 mm; five slices obtained in one acquisition; acquisition time, 4 min 42 s; matrix, 128×128; FOV, 240 mm; 50 averages.

### DCE MRI

After ASL MRI, T1-weighted DCE MRI was performed using the following parameters: TR /TE, 82.6 ms /3.63 ms; 10 slices; slice thickness, 6 mm; measurement interval, 9.54 s; matrix, 96×256; FOV, 310 mm; 75 measurements; contrast media (0.1 mmol /kg body weight of Gd-DTPA, Magnevist, Schering, Berlin, Germany); infusion time 30 s starting with the fifth measurement. With a pharmacokinetic two-compartment model, the parameter amplitude, reflecting the degree of MRI signal enhancement, and the exchange rate constant *k*~*ep*~ that reflects microvascular permeability were calculated \[[@b13], [@b14]\]. Typical criteria for malignancy in enhancement kinetics of DCE MRI are rapid and high-amplitude wash-in followed by a relatively rapid wash-out. Thus, malignant lesions tend to have high rate constants or transfer constants of exchange reflected as bright colors on parametric images \[[@b5]\]. Benign lesions enhance and wash out slowly and show only minimal change in color on parametric images \[[@b5]\]. Regarding enhancement kinetics, amplitude reflects the magnitude of the enhancement curve and a small *k*~*ep*~ reflects a more delayed enhancement than a high *k*~*ep*~ \[[@b5]\].

After DCE MRI, the imaging protocol on the Magnetom Vision Plus MR unit was finished by an axial T1-weighted spin-echo sequence (600 ms /20 ms).

Data analysis
-------------

### Region-of-interest (ROI) analysis

Analysis of perfusion and DCE MRI was performed using ROI analysis according to the recommendations of earlier studies \[[@b15], [@b16]\]. ROIs were placed after consensus of two radiologists with 6 and 12 years of experience in the field of CNS MRI. To avoid the risk of calculating maps from normal vessels, the serial T2 ^\*^-weighted images from the arterial to venous phases as well as the standard MR images were scrutinized before placing the ROIs. The ROIs placed within the tumor or perifocally had a size of at least 20 pixels. The perfusion values were calculated in four regions of interest within both areas of the peritumoral region and within the enhancing tumor. In order to readily appreciate the inherent heterogeneity of brain tumors, the four ROIs were defined as follows: ROI 1, 'Tumor', includes all non-necrosis-enhancing tumor tissue, or, if the lesion did not show enhancement, the whole non-necrotic T2-hyperintense, T1-hypointense tumor tissue avoiding perifocal edema. ROI 2, 'Max Tumor', was placed on the tumor area with maximum CBF or CBV values on parameter images by identifying regions of maximal tumor blood flow or volume from color maps \[[@b9], [@b17], [@b18]\]. For DCE MRI, the ROI 'Max Tumor' was placed on the tumor area with the highest amplitude and *k*~*ep*~ on parameter images. ROI 3, 'Perifocal (T2high)', was placed within a 1-cm distance from the outer enhancing tumor margin in T2-hyperintense regions \[[@b15]\]. The ROI 4, 'Perifocal (T2normal)', was placed next to the T2-hyperintense perifocal area in the normal-appearing ipsilateral brain tissue.

Additionally, in order to average distribution of flow values in the different regions of the brain, both the contralateral gray and white matter, which appeared normal on conventional MRI, were evaluated by six ROIs of 6 pixels in size each \[[@b16], [@b19]\].

### DSC MRI intensity--time curve analysis

Besides calculation of CBV maps, we determined the intensity--time curve within the ROI with the highest rrCBV value. By this, differentiation between CNS lymphoma and glioblastoma has been reported \[[@b9]\] because CNS lymphomas showed a significant undershoot below baseline after the first pass of contrast medium resulting from T1 effects, whereas no or only a slight undershoot below baseline was observed in glioblastomas. The two radiologists assessed, in consensus, in a dichotomous fashion whether there was undershoot.

Perfusion analysis using ASL MRI
--------------------------------

For each ASL measurement, rrCBF ratios of gray to white matter (GM/WM) and ROIs 1 to 4/GM were calculated as major parameters of interest because of underestimation of white matter perfusion using ASL and other methodological considerations that are in favor of GM as internal reference as described previously \[[@b16], [@b19]\]. Additionally, ATT was determined in all ROIs.

### Analysis of spectroscopic imaging data

At a TE of 135 ms, signal intensities of Cho (3.2 ppm), Cr (3.0 ppm), and NAA (2.0 ppm) were calculated by fit and integration of the resonances in postprocessed Fourier spectra. In addition, all ^1^H spectra were inspected for the presence of resonances of lactate (inverted lactate doublet at 1.32 ppm) and lipid resonances (CH ~3~: 0.9 ppm, --CH ~2~--: 1.3 ppm) \[[@b8]\]. Two readers with 6 years of experience in the field of MR spectroscopy assessed, in consensus, in a dichotomous fashion, whether there were lipids or lactate present. The metabolite ratios Cho/Cr, Cho/NAA, and NAA/Cr \[[@b15], [@b20]\] were calculated in voxels corresponding to the ROIs defined for perfusion and DCE analysis, i.e. 'Tumor', 'Max Tumor Perfusion', and 'Perifocal (T2high)' for the different lesions. To ensure quality control and acceptable quality of spectroscopic data, control spectra were obtained from the normal-appearing white matter in the contralateral hemisphere \[[@b18]\]. Additionally, the maximum metabolite tumor ratios on the Cho/NAA and Cho/Cr parameter maps and the minimum metabolite tumor ratios on the NAA/Cr parameter maps were identified. MRI and MRSI analysis was performed without knowledge of the final histologic tumor diagnosis.

Histology
---------

Gross total resection was obtained in 56 of all 79 brain tumors. Stereotactic biopsy was performed in the other 23 tumors because in toto resection was either not surgically possible or not indicated. Stereotactic biopsies were guided by imaging findings, including findings of functional MRI \[[@b1], [@b6]\]. This means that in cases of tumors with heterogeneous perfusion, stereotactic biopsies were directed to the area with highest perfusion. Surgical specimens were paraffin embedded after 4% formalin fixation (buffered in phosphate-buffered saline), and 1- μm slices were prepared for hematoxylin-eosin (HE) staining. The tumor types were histopathologically classified according to World Health Organization criteria and afterward were divided into the following groups in accordance with previous studies \[[@b21], [@b22]\]: well-differentiated or low-grade gliomas (grade 2), anaplastic gliomas (grade 3), glioblastoma multiforme (grade 4), CNS lymphomas, metastases, meningiomas, and miscellaneous nonglial circumscribed tumors. Grading of gliomas was based on histologic examination of the most aggressive neoplastic tissue area present in specimens obtained by surgical resection or biopsy \[[@b23]\]. In addition to histologic grading, tumor proliferation activity was assessed morphometrically by a senior neuropathologist after immunohistologic staining with the monoclonal antibody against Ki-67 antigen MIB-1 (Dako, Glostrup, Denmark). To visualize microvessels in the tumor specimens, immunoperoxidase staining for CD31 and factor VIII (Dako) were performed on 1- μm sections. All sections were then counterstained with hematoxylin. Immunohistochemically stained slides were examined field by field at a magnification of ×200 to identify the area revealing the most intense vascularization, i.e. the 'hot spot'. The magnification was then changed to ×400 to determine the number of vessels per square millimeter within the hot spot. According to established proceedings, any stained endothelial cell or endothelial cell cluster, with or without a lumen that was clearly separated from adjacent microvessels, as well as any glomeruloid vascular proliferation, was considered as a single countable microvessel.

Statistical analysis
--------------------

The statistical analysis was carried out using the software package R, version 2.1.1 \[[@b24]\]. Vessel density, proliferation index, rrCBF and rrCBV ratios, parameters arising from DCE MRI and MRSI, and ATT were correlated with each other by calculating Pearson's correlation coefficients and the 95% confidence intervals (CIs) (coefficients \>0.5 indicate a moderately positive correlation) \[[@b25]\]. Receiver operating characteristic (ROC) analysis was performed for tumor classification and glioma grading. Nonparametric estimates and 95% CIs for the area under the ROC curves (AUCs) were calculated with AUC = 1, indicating perfect discrimination, and AUC = 0.5, indicating no or random discrimination \[[@b26]\]. Optimal thresholds for tumor classification and glioma grading were determined \[[@b27]\]. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) together with the 95% CIs for correct tumor classification of glioblastoma vs. lymphoma, metastasis, anaplastic glioma, or low-grade glioma were calculated using these threshold values \[[@b28]\]. The association of the different variables/parameters with glioma grading and tumor classification was evaluated by analysis of variance (ANOVA). If the global F test was significant $\documentclass[12pt]{minimal} 
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Results
=======

Histology
---------

In our patient population with a total of 79 brain tumors, 75 were localized intra-axially and four were extra-axial. Thirty-five were classified as glioblastomas (diagnosis based on stereotactic biopsy samples \[SB\], 12), 11 as anaplastic gliomas (SB, 6), nine as grade 2 gliomas (SB, 1), 10 as CNS lymphomas (all high-grade diffuse large cell non-Hodgkin lymphomas of B-cell type and periventricularly localized; SB, 3), seven as adenocarcinoma metastases (SB, 1), four as grade 1 meningiomas (secretory, 2; meningothelial, 1; microcystic, 1), and two as other nonglial tumors. Except for the meningiomas, none of the other tumors had dural localization. The one low-grade glioma included in our study that was diagnosed based on stereotactic biopsy had a homogeneous appearance both on conventional MRI and functional MRI and lacked focal malignant transformation at histology, assuming that the specimen was representative. Vessel density was higher in glioblastomas than grade 3 (*p*=0.004) and grade 2 gliomas (*p*\<0.001), CNS lymphomas (*p*=0.01), and metastases (*p*=0.01), but not higher than in meningiomas (*p*=0.1). Proliferation index was higher in glioblastomas than grade 2 gliomas (*p*=0.01), but proliferation activity was not higher compared to grade 3 gliomas (*p*=0.2) and metastases (*p*=0.4). CNS lymphomas had a higher proliferation index than glioblastomas (*p*\<0.001 (see Table E-1 on the *Neurology* web site at <http://www.neurology.org>).

DSC MRI
-------

In tumor tissue of glioblastomas, rrCBV was higher than grade 3 (*p*=0.04) and grade 2 gliomas (*p*=0.04), but not in the peritumoral T2-weighted hyperintense area (Table E-1). In all CNS lymphomas, there was a significant undershoot below the baseline after the first pass of contrast medium that was observed in 6% of glioblastomas and 50% of meningiomas, but was absent in grades 2 and 3 gliomas (Fig. E-1). ROC analysis yielded AUC values of 0.98 (95% CI: 0.98--0.98) using the ROI 'Max Tumor' and 0.93 (95% CI: 0.93--0.94) for the ROI 'Perifocal (T2high)' for discrimination of glioblastomas from CNS lymphomas or metastases.

ASL MRI
-------

Detailed results are given for the Q2TIPS (Table E-2) and for the ITS-FAIR sequence (Tables E-3 and E-4). rrCBF was higher in tumor tissue of glioblastomas than grade 3 (Q2TIPS: *p*=0.01, ITS-FAIR: *p*=0.03) and grade 2 gliomas (Q2TIPS: *p*=0.003, ITS-FAIR: *p*=0.002). rrCBF was higher in tumor tissue of glioblastomas than CNS lymphomas (Q2TIPS: *p*=0.003, ITS-FAIR: *p*=0.03, [Fig. 1](#F1){ref-type="fig"}), but not when compared with metastases (Q2TIPS: *p*=0.9, ITS-FAIR: *p*=0.7) and meningiomas (Q2TIPS: *p*=0.4, ITS-FAIR: *p*=0.3). rrCBF was higher in the peritumoral T2-weighted hyperintense region of glioblastomas when compared with meningiomas, metastases, and CNS lymphomas (*p*=0.001 for all entities and both ASL sequences ([Fig. 2](#F2){ref-type="fig"}, Fig. E-2). In all tumor entities, both rrCBF and ATT of the peritumoral T2-weighted normal brain parenchyma and the contralateral normal brain tissue were not significantly different. In tumors with high perfusion, such as glioblastomas and meningiomas, ATT was reduced compared with normal brain parenchyma (*p*\<0.001, Table E-4). ATT was shorter both in tumor (*p*=0.001) and peritumoral T2-hyperintense regions (*p*=0.002) of glioblastomas when compared with CNS lymphomas. ROC analysis yielded AUC values for the ROI 'Perifocal (T2high)' of 0.96 (Q2TIPS, 95% CI: 0.95--0.96), 0.95 (ITS-FAIR, 95% CI: 0.95--0.95), and 0.85 (ATT, 95% CI: 0.84--0.86) for discrimination of glioblastomas from CNS lymphomas or metastases. Figure 1A 63-year-old woman with anaplastic glioma of the splenium (a, b) and 66-year-old woman with CNS lymphoma (c, d). (a, c) Contrast-enhanced T1-weighted MRI; (b, d) relative regional CBF perfusion maps obtained by Q2TIPS arterial spin labeling MRI. Tumor blood flow normalized on gray matter is higher in anaplastic glioma than in CNS lymphoma (5.4 vs. 0.6, arrows). Figure 2A 34-year-old man with glioblastoma. Fluid-attenuated inversion recovery MRI (a), contrast-enhanced T1-weighted MRI (b), relative regional cerebral blood flow perfusion map obtained by Q2TIPS arterial spin labeling MRI (c), and proton MR spectroscopic imaging superimposed on a T2-weighted MR image showing choline/creatine metabolite ratios (d). The contrast-enhancing areas of the glioblastoma show elevated tumor blood flow normalized on gray matter (8.2). The peritumoral T2-weighted hyperintense nonenhancing area (arrows) also has a high blood flow normalized on gray matter (1.7) and shows elevated choline/creatine metabolite ratios, suggesting tumor infiltration.

Spectroscopic imaging
---------------------

Detailed results for MRSI are given (Table E-5). In the different glioma grades, signal intensity ratios of Cho/Cr, NAA/Cr, and Cho/NAA were not significantly altered both for tumor and perifocal regions. Also, signal intensity ratios of Cho/Cr, NAA/Cr, and Cho/ NAA within tumor tissue were not significantly different between glioblastomas, CNS lymphomas, and metastases. However, MRSI demonstrated pathologic spectra with elevated Cho levels and thus increased Cho/NAA ratios in the perifocal T2-weighted hyperintense region in all cases of gliomas and CNS lymphomas but not in metastases, meningiomas, and contralateral normal brain tissue ([Fig. 2](#F2){ref-type="fig"}; Fig. E-2). Lactate and lipid signals were found in all tumors except in low-grade gliomas. The maximum metabolite tumor ratios on the Cho/NAA and Cho/Cr parameter maps and the minimum metabolite tumor ratios on the NAA/Cr parameter maps were not colocalized with maximum tumor perfusion. ROC analysis yielded AUC values of 0.81 (Cho/NAA, 95% CI: 0.80--0.83) and 0.77 (Cho/Cr, 95% CI: 0.74--0.80) using tumor ROIs for discrimination of glioblastomas from CNS lymphomas. AUC values were 0.96 (Cho/Cr, 95% CI: 0.96--0.97) and 0.95 (Cho/NAA, 95% CI: 0.95--0.96) using perifocal T2-hyperintense regions for discrimination of glioblastomas from metastases.

DCE MRI
-------

Meningiomas had the highest amplitude values, higher than glioblastomas (*p*=0.02), whereas *k*~*ep*~ values were not different (*p*=0.9). Amplitude and *k*~*ep*~ values were higher in glioblastomas (amplitude: *p*\<0.001, *k*~*ep*~: *p*=0.003) and grade 3 gliomas (amplitude: *p*=0.001, *k*~*ep*~: *p*=0.03) than in grade 2 gliomas. Amplitude and *k*~*ep*~ values were not significantly different between glioblastomas, grade 3 gliomas, CNS lymphomas, and metastases (Table E-6). ROC analysis yielded AUC values of 0.68 (amplitude, 95% CI: 0.66--0.69) and 0.53 (*k*~*ep*~, 95% CI: 0.51--0.55) using the ROI 'Max Tumor' for discrimination of glioblastomas from CNS lymphomas or metastases.

Correlation analysis
--------------------

Results of correlation analysis are given in [Table 2](#T2){ref-type="table"}. Tumor blood volume and vessel density were correlated (*r*=0.51). When comparing other intratumoral functional MRI parameters with proliferation index or vessel density, correlation coefficients did not reach a value of ±0.5 that would indicate a moderate correlation. In tumor tissue, the parameter amplitude was correlated with rrCBF and rrCBV. When tumor blood flow measured by the Q2TIPS ASL sequence was high, the ITS-FAIR ASL sequence also measured a high tumor blood flow (*r*=0.64). The higher the tumor blood flow was with either ASL sequence, the shorter was the arterial transit time (ITS-FAIR, *r*=−0.56; Q2TIPS, *r*=−0.57). Although no substantial correlation was observed between Cho/NAA and Cho/Cr in tumor tissue, both metabolite ratios were correlated in healthy brain tissue (*r*=0.64) and perifocal T2-hyperintense regions (*r*=0.74). Table 2Correlation coefficients for tumor regions of interestCBVCBF (Q2TIPS)CBF (ITS-FAIR)Cho/NAACho/CrAmplitudeCBV---0.47 ^\*^ (0.15--0.69)0.13 ^\*^ (− 0.32--0.53)0.75 ^\*†^ (0.45--0.89)0.20 ^\*^ (− 0.26--0.59)0.56 ^\*†^ (0.26--0.77)CBF (Q2TIPS)0.31 (0.0--0.63)---0.64 ^\*†^ (0.46--0.77)0.44 ^\*^ (0.13--0.67)0.12 ^\*^ (− 0.22--0.44)0.61 ^\*†^ (0.43--0.73)CBF (ITS-FAIR)0.11 (−0.44--0.58)0.75 ^†^ (0.57--0.86)---0.24 ^\*^ (−0.29--0.66)0.78 ^\*†^ (0.49--0.91)0.53 ^\*†^ (0.31--0.70)Cho/NAA0.74 ^†^ (0.38--0.90)0.58 ^†^ (0.26--0.79)0.31 (− 0.22--0.70)---0.24 ^\*^ (− 0.13--0.54)0.19 ^\*^ (− 0.17--0.51)Cho/Cr0.31 (−0.22--0.70)0.21 (− 0.19--0.55)0.47 (− 0.05--0.79)0.20 (− 0.24--0.56)---0.24 ^\*^ (− 0.13--0.55)Amplitude0.43 (0.0--0.73)0.58 ^†^ (0.35--0.74)0.69 ^†^ (0.46--0.82)0.23 (− 0.20--0.59)0.35 (−0.09--0.67)---^\*^Data represent results for all brain tumors. Other data represent the results only for all glioma patients. ^†^ Correlation coefficients indicating at least a moderate correlation. 95% confidence intervals are presented in parentheses. CBV = cerebral blood volume; CBF = cerebral blood volume; Q2TIPS = second version of quantitative imaging of perfusion by using a single subtraction with addition of thin-section periodic saturation after inversion and a time delay sequence; ITS-FAIR = inflow turbo-sampling, echo-planar, flow-sensitive, alternating inversion recovery sequence; Cho = choline; NAA = *N*-acetyl aspartate; Cr = creatine.

Differential diagnosis
----------------------

For the discrimination of glioblastomas from CNS lymphomas, both DSC and ASL perfusion MRI had higher predictive values than MRSI (Table E-7). Sensitivity, specificity, PPV, and NPV for DSC and ASL perfusion MRI were comparable when using ROIs within tumor tissue or perifocal T2-hyperintense regions. The Q2TIPS ASL perfusion technique yielded slightly higher predictive values than the ITS-FAIR technique. For Q2TIPS ASL MRI, sensitivity was 97%, specificity was 80%, PPV was 94%, and NPV was 89%, with a threshold value of 1.2 for rrCBF within tumor tissue ([Table 3](#T3){ref-type="table"}); for ITS-FAIR ASL MRI, sensitivity was 89%, specificity was 83%, PPV was 96%, and NPV was 63%, with a threshold value of 1.1 for rrCBF; and for DSC MRI, sensitivity was 100%, specificity was 50%, PPV was 90%, and NPV was 100%, with a threshold value of 1.4 for rrCBV. Table 3Sensitivity, specificity, and predictive values for differentiation of glioblastoma from CNS lymphoma or metastasis and for glioma grading using arterial spin-labeling MRIThreshold valueSensitivity (%)Specificity (%)PPV (%)NPV (%)Glioblastoma vs. CNS lymphomarrCBF of 1.297 (87--99)80 (66--89)94 (83--98)89 (76--95)Glioblastoma vs. metastasis ^\*^rrCBF of 0.5100 (91--100)71 (56--83)94 (83--98)100 (91--100)Glioblastoma vs. grade 3 gliomarrCBF of 1.497 (87--99)50 (36--64)84 (71--92)86 (73--93)Glioblastoma vs. grade 2 gliomarrCBF of 1.694 (82--98)78 (63--88)94 (82--98)78 (63--88)Grade 3 vs. grade 2 gliomarrCBF of 1.092 (73--98)33 (17--55)65 (44--81)75 (54--89)^\*^Results for differentiation between glioblastoma and metastasis are given for peritumoral T2-hyperintense regions. Results are given for tumor regions of interest using the second version of quantitative imaging of perfusion by using a single subtraction with addition of thin-section periodic saturation after inversion and a time delay arterial spin-labeling sequence. All values presented are significant; 95% CIs are presented in parentheses. PPV = positive predictive value; NPV = negative predictive value; rrCBF = relative regional cerebral blood flow.

For the discrimination of glioblastomas from metastases by analyzing perifocal T2-hyperintense regions, perfusion MRI had higher predictive values than MRSI (Table E-8). For Q2TIPS ASL MRI, sensitivity was 100%, specificity was 71%, PPV was 94%, and NPV was 100%, with a threshold value of 0.5 for rrCBF in perifocal T2-hyperintense regions ([Table 3](#T3){ref-type="table"}). Results of the Q2TIPS ASL sequence were slightly better than results of the ITS-FAIR ASL sequence (Table E-8).

Results for glioma grading are given in [Table 3](#T3){ref-type="table"}. Among the 11 nonenhancing tumors of our study, two had areas of distinctly higher perfusion than gray matter, underwent gross total resection, and were classified as grade 3 gliomas at histology. The other nine nonenhancing tumors had a homogeneous appearance both on conventional and functional MRI with no evidence of increased tumor vascularity on perfusion maps and were classified as grade 2 gliomas at histology. Threshold values of rrCBF = 1.4 and 1.6 provided minimum errors for determining a glioblastoma from a grade 3 or 2 glioma. DSC and ASL perfusion MRI had comparable predictive values for glioma grading. DSC MRI obtained higher AUC values than both ASL sequences and other MRI techniques, such as MRSI, for the ROI 'Max Tumor' (Table E-9).

Discussion
==========

In this study, we compared different functional MRI techniques, such as DSC and ASL perfusion MRI, DCE MRI, and MRSI with histologic findings in untreated brain tumors, such as vessel density and proliferation index. We presented characteristic MRI findings of various brain neoplasms in perfusion and spectroscopic imaging and assessed their value for specific tumor diagnosis. Additionally, sensitivity, specificity, PPV, and NPV for discriminating brain tumors based on these MR-derived functional parameters were presented.

The results of ASL perfusion MRI in tumor and normal brain tissue were in accordance with those of previous reports \[[@b3], [@b4], [@b16], [@b19]\]. Highest signal intensities on ASL images in meningiomas and lowest rrCBF values in CNS lymphomas and low-grade gliomas have been reported before in a small patient population \[[@b3]\]. We observed a significantly higher tumor blood flow in high-grade than in low-grade gliomas in accordance with previous observations \[[@b4]\]. Moreover, we could prove by using the ITS-FAIR ASL approach that a high brain tumor perfusion is related to a short arterial transit time, as previously hypothesized \[[@b3]\]. As reported in healthy brain tissue \[[@b19]\], rrCBF values obtained by the Q2TIPS and ITS-FAIR ASL sequence were also correlated in tumor tissue.

In all tumor entities, the parameter amplitude was correlated with rrCBF and rrCBV, reflecting the fact that all these parameters measure tumor vascularity. However, in our study, no strong correlation between rrCBF and rrCBV was observed. The reason for this may be that the two parameters were measured in two separate MRI examinations. For gliomas, MRI- and MRSI-derived parameters were associated with vascularity, proliferation index, and tumor type. Correlation analysis of MR-derived parameters and histologic findings only showed a moderate correlation of rrCBV and vessel density. This may be due to several reasons. rrCBV measurements by DSC MRI are falsified by contrast agent leakage in case of blood-barrier-disruption or absence, such as in extra-axial lesions \[[@b1]\]. Blood flow is underestimated by ASL sequences at low flow rates, i.e. hypovascularized lesions or white matter \[[@b4]\]. Attempts to correlate DCE MRI results with vessel density have met with mixed success \[[@b5]\]. This is not entirely unexpected because vessel density is an anatomic index, whereas DCE MRI is an *in vivo* assay dependent on vascular characteristics in living tissue \[[@b5]\]. Moreover, histopathologic assessment is limited by inherent sampling error associated with stereotactic biopsy, particularly regarding microvessel density. Tumors may be very heterogeneous, and in our study, we included both homogeneous- and heterogeneous-appearing tumors. This may explain why strong correlations between Cho and proliferation activity have only been described in homogeneous gliomas \[[@b30]\]. The Cho/NAA ratios in tumor and normal brain tissue observed in our study are in good agreement with other studies \[[@b20]\]. Areas of highest Cho signal and perfusion did not always correspond \[[@b6]\]. This may be due to the fact that MRS and perfusion MRI are measuring different pathophysiologic aspects of tumoral activity.

Although contrast-enhancing lesions in contact with the CSF system and without necrosis are characteristic of CNS lymphoma \[[@b31]\], it can be difficult, sometimes even impossible, to distinguish high-grade gliomas from CNS lymphomas on conventional MRI \[[@b9]\]. We examined a homogeneous group of high-grade diffuse large cell non-Hodgkin lymphomas of the B-cell type and demonstrated that perfusion MRI enabled the discrimination of glioblastomas from this CNS lymphoma group with high predictive values. Tumor blood flow and volume were significantly higher in glioblastomas than in CNS lymphomas, as also reported previously \[[@b1], [@b9]\]. The reason why we were not able to discriminate glioblastomas from CNS lymphomas by the increased lipid signal of CNS lymphomas as reported before with a TE of 20 ms \[[@b20]\] might be our use of a TE of 135 ms because lipid peaks are more readily appreciated at short echo times \[[@b6]\]. A TE of 135 ms has the advantage of a better detection of lactate and is thus often used for evaluation of intracranial neoplasms \[[@b6]\]. Because of extensive necrotic areas observed in some glioblastomas and metastases, the Cho signal may be influenced in such lesions by partial volume effects, although in our study necrotic areas were avoided in analysis \[[@b6]\]. This may be another reason why metabolite ratios of different tumor entities were not significantly different in our study.

Correct grading of gliomas has significant clinical impact because adjuvant therapy after surgery is usually administered to high-grade but not low-grade gliomas. Histopathology as gold standard based on biopsy samples is limited due to the inherent sampling error in these heterogeneous tumors \[[@b6]\]. In accordance with previous observations, high-grade gliomas had higher rrCBV \[[@b18], [@b32]--[@b34]\], rrCBF \[[@b4], [@b35]\], and Cho levels \[[@b18], [@b20]\] than low-grade gliomas. However, we observed a significant overlap of metabolite ratios and tumor perfusion between high- and low-grade gliomas, which may be explained by the inherent glioma heterogeneity and the sampling error of biopsy samples, as observed previously \[[@b1], [@b6]\], although all low-grade gliomas in our study had a homogeneous appearance both on conventional MRI and functional MRI with no focal areas of contrast enhancement, elevated perfusion, or increased MRSI metabolites and even lacked focal malignant transformation in histology. Nevertheless, the use of perfusion measurements and metabolite ratios increased the sensitivity, specificity, PPV, and NPV compared with conventional MRI (sensitivity, 73%; specificity, 65%; PPV, 86%; and NPV, 44%) \[[@b18]\] for discriminating high- from low-grade gliomas. The threshold values presented in our study can be used in a clinical setting to evaluate tumors preoperatively for histologic grade and provide a means for guiding treatment and predicting postoperative patient outcome. In comparison with a previous study that only distinguished between low- and high-grade gliomas \[[@b18]\], we could demonstrate that MR perfusion and spectroscopic imaging provide better prospective grading of gliomas than conventional MRI, even when discriminating glioblastomas from grade 3 gliomas and grade 3 from grade 2 gliomas. However, because of the low specificity, especially when differentiating grade 3 from grade 2 gliomas, these functional MRI techniques have limited utility for an individual patient in making a specific diagnosis, but they may be of great clinical value for biopsy guidance because of the potential glioma heterogeneity with high-grade components that might be interspersed among low-grade components. Thus, it may become possible to reduce potential errors due to sampling bias from a stereotactic biopsy \[[@b21]\].

Although conventional MRI characteristics of solitary metastases and primary high-grade gliomas may sometimes be similar, MR perfusion and spectroscopic imaging enable distinction between the two \[[@b15], [@b36]\]. Although both intratumoral metabolite ratios \[[@b6]\], rrCBV or rrCBF values did not allow for discrimination between the two entities, analyzing the peritumoral T2-weighted hyperintense region allows discrimination between high-grade gliomas and metastases or, as indicated by our initial results, grade 1 meningiomas. High Cho and reduced NAA signals as well as elevated perfusion in the peritumoral region of the lesion represent with high specificity glioma in differentiation of glioma from metastasis or grade 1 meningioma. The decrease in NAA is a marker of neuronal or axonal injury and loss, while the elevated Cho concentration suggested an increase of cell membrane synthesis and turnover \[[@b6]\] and an increased number of cells \[[@b37]\]. Gliomas are known to infiltrate along vascular channels, whereas peritumoral regions in metastases or grade 1 meningiomas contain no tumor cells or vascular endothelial proliferation but almost purely vasogenic edema \[[@b15], [@b38]\]. Hence, MR perfusion and spectroscopic imaging allow us to readily appreciate tumor extension past obvious gross anatomic boundaries on conventional MRI.

In our study, perfusion MRI measurements had the superior diagnostic performance in predicting glioma grade and in differentiating glioblastoma from other tumor entities. Because of the shorter acquisition time and the better predictive values in differential diagnosis, we would favor the use of perfusion over spectroscopic imaging on a 1.5-T MR unit. This may be the case in patients with reduced physical condition and compliance, which results in a limited imaging time. DCE MRI offered little information for differential diagnosis of enhancing brain tumors. This technique may be rather used for treatment monitoring of brain tumors, especially of extraaxial lesions \[[@b14]\], because the technique is not as susceptible to susceptibility artifacts arising from bone and air as DSC MRI. For intra-axial lesions, the value of DSC MRI for treatment monitoring \[[@b39]\] and biopsy targeting \[[@b1], [@b34]\] has already been reported. Although functional MRI techniques have a better diagnostic performance than conventional MRI techniques in distinguishing different tumor entities, functional MRI cannot eliminate the need for a biopsy and histologic confirmation.
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